George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update Re. Nasdaq Minimum Bid Price Requirement

31 May 2018 07:25

RNS Number : 7618P
Akers Biosciences, Inc.
30 May 2018
 

May 31, 2018

 

Akers Biosciences, Inc.

 

Update Re. Nasdaq Minimum Bid Price Requirement

 

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, further to its announcement dated December 1, 2017, on May 30, 2018, the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") granted the Company a 180-day extension to meet the requirement of a minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days (the "Bid Price Requirement") for continued inclusion on the Nasdaq Capital Market.

As previously disclosed, the Company received notice from Nasdaq on November 28, 2017, that it was not in compliance with the Bid Price Requirements for its common stock. Per Nasdaq rules, the Company was afforded an initial 180 calendar days to regain compliance with the Bid Price Requirement. The Company provided a written notice of its intention to cure the deficiency during the second 180 calendar day compliance period by effecting a reverse stock split, if necessary.

Following a review, Nasdaq determined that the Company was eligible for an additional 180 calendar days to regain compliance with the Bid Price Requirement. If at any time during the second 180 calendar day period the closing bid price of the Company's common stock, for the required minimum 10 consecutive business day period, meets the Bid Price Requirement and provided that the Company meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards, Nasdaq will provide the Company with written confirmation that it is compliant with the Bid Price Requirement and this matter will be closed.

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Note Regarding Forward-Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. The forward-looking statements include statements or expectations regarding the Company's compliance with the Bid Price Requirement, the Company's continued listing on Nasdaq, other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission and other future events. Such statements may include, without limitation, statements with respect to the Company's plans, compliance with the requirements of various regulatory agencies, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions, as they relate to the Company, its subsidiaries, or its management. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, performance, prospects, and opportunities to may differ materially from those set forth in, or implied by, the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For more information:

 

Akers Biosciences, Inc.

John J. Gormally, Chief Executive Officer

Tel. +1 856 848 8698

 

finnCap (UK Nominated Adviser and Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel. +44 (0)20 7220 0500

 

Vigo Communications (Global Public Relations)

Ben Simons / Fiona Henson

Tel. +44 (0)20 7830 9704

Email: akers@vigocomms.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDLFFELEVIIVIT
Date   Source Headline
4th Jun 20147:00 amRNSDistribution Agreement Signed
16th May 20147:00 amRNSAgreement to Market Rapid Tests in India
14th May 201412:00 pmRNSFirst Quarter Results
7th May 20147:00 amRNSInternational Distribution Agreement
30th Apr 20147:01 amRNSClinical Trials for PIFA PLUSS Chlamydia Assay
28th Mar 201411:00 amRNSFinal Results
27th Mar 201411:00 amRNSSenior Managerial Appointment
12th Mar 20145:12 pmRNSDirectorate Change
11th Mar 20144:30 pmRNSNASDAQ IPO Update
11th Mar 20144:29 pmRNSHolding(s) in Company
31st Jan 20145:30 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSDirector/PDMR Shareholding
31st Jan 20147:00 amRNSTotal Voting Rights
27th Jan 20142:46 pmRNSAppointment of Non-Executive Director
24th Jan 20147:30 amRNSRestoration - Akers Biosciences, Inc
23rd Jan 20146:10 pmRNSPricing of Offering & Recommencement of Trading
23rd Jan 20147:30 amRNSSuspension - Akers Biosciences, Inc.
23rd Jan 20147:30 amRNSTemporary Suspension
7th Jan 20145:27 pmRNSCorrection: SEC filings available on website
7th Jan 20144:54 pmRNSSEC filings available on Company's web site
2nd Jan 201410:37 amRNSHolding(s) in Company
31st Dec 201312:34 pmRNSCorrection: Total Voting Rights
31st Dec 20138:00 amRNSTotal Voting Rights
30th Dec 20137:00 amRNSIssue of Equity
23rd Dec 20137:00 amRNSPlacing of Shares
9th Dec 20137:00 amRNSProposed NASDAQ Listing
6th Dec 20137:00 amRNSDirector Dealing
5th Dec 20139:51 amRNSHolding(s) in Company
29th Nov 20134:00 pmRNSTotal Voting Rights
18th Nov 20137:00 amRNSShare Capital Consolidation
15th Nov 20132:37 pmRNSUnaudited results for nine months ended 30.09.2013
7th Nov 20134:55 pmRNSHolding(s) in Company
23rd Oct 20133:09 pmRNSHolding(s) in Company
17th Oct 20132:09 pmRNSHolding(s) in Company
17th Oct 20131:54 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results for Six Months Ended 30 June 2013
15th Aug 20138:55 amRNSHolding(s) in Company
8th Aug 20137:00 amRNSProposed NASDAQ Listing
23rd Jul 20137:00 amRNSDirector's Dealing
19th Jul 20137:00 amRNSTrading Statement
10th Jul 20139:51 amRNSHolding(s) in Company
1st Jul 20139:41 amRNSAppointment of Non-Executive Directors
26th Jun 20137:00 amRNSPreliminary Results for Year End 31 December 2012
14th Jun 201312:25 pmRNSHolding(s) in Company
13th Jun 20131:24 pmRNSExtension of Agreement & $1.6m Subscription
10th Apr 20137:00 amRNSTrading Update
27th Feb 20138:39 amRNSFinal Award of NF Mark
19th Feb 20137:00 amRNSTrading Update
20th Dec 20125:35 pmRNSResult of AGM
11th Dec 20127:00 amRNS3.5m unit Order for Breath Alcohol tubes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.